| Autor: |
Winterburn TJ; School of Biosciences, Cardiff University, UK Actelion Pharmaceuticals Ltd, Allschwil, Switzerland., Phylip LH; School of Biosciences, Cardiff University, UK Actelion Pharmaceuticals Ltd, Allschwil, Switzerland., Bur D; School of Biosciences, Cardiff University, UK Actelion Pharmaceuticals Ltd, Allschwil, Switzerland., Wyatt DM; School of Biosciences, Cardiff University, UK Actelion Pharmaceuticals Ltd, Allschwil, Switzerland., Berry C; School of Biosciences, Cardiff University, UK Actelion Pharmaceuticals Ltd, Allschwil, Switzerland., Kay J; School of Biosciences, Cardiff University, UK Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. |
| Abstrakt: |
Yeast IA(3) aspartic proteinase inhibitor operates through an unprecedented mechanism and exhibits a remarkable specificity for one target enzyme, saccharopepsin. Even aspartic proteinases that are very closely similar to saccharopepsin (e.g. the vacuolar enzyme from Pichia pastoris) are not susceptible to significant inhibition. The Pichia proteinase was selected as the target for initial attempts to engineer IA(3) to re-design the specificity. The IA(3) polypeptides from Saccharomyces cerevisiae and Saccharomyces castellii differ considerably in sequence. Alterations made by deletion or exchange of the residues in the C-terminal segment of these polypeptides had only minor effects. By contrast, extension of each of these wild-type and chimaeric polypeptides at its N-terminus by an MK(H)(7)MQ sequence generated inhibitors that displayed subnanomolar potency towards the Pichia enzyme. This gain-in-function was completely reversed upon removal of the extension sequence by exopeptidase trimming. Capture of the potentially positively charged aromatic histidine residues of the extension by remote, negatively charged side-chains, which were identified in the Pichia enzyme by modelling, may increase the local IA(3) concentration and create an anchor that enables the N-terminal segment residues to be harboured in closer proximity to the enzyme active site, thus promoting their interaction. In saccharopepsin, some of the counterpart residues are different and, consistent with this, the N-terminal extension of each IA(3) polypeptide was without major effect on the potency of interaction with saccharopepsin. In this way, it is possible to convert IA(3) polypeptides that display little affinity for the Pichia enzyme into potent inhibitors of this proteinase and thus broaden the target selectivity of this remarkable small protein. |
